NO20063720L - Antidiabetiske oksazolidiendioner og tiazolidiendioner - Google Patents
Antidiabetiske oksazolidiendioner og tiazolidiendionerInfo
- Publication number
- NO20063720L NO20063720L NO20063720A NO20063720A NO20063720L NO 20063720 L NO20063720 L NO 20063720L NO 20063720 A NO20063720 A NO 20063720A NO 20063720 A NO20063720 A NO 20063720A NO 20063720 L NO20063720 L NO 20063720L
- Authority
- NO
- Norway
- Prior art keywords
- thiazolidinediones
- dione
- diabetes
- type
- oxazolidinediones
- Prior art date
Links
- 229940123464 Thiazolidinedione Drugs 0.000 title 1
- 230000003178 anti-diabetic effect Effects 0.000 title 1
- 239000003472 antidiabetic agent Substances 0.000 title 1
- 150000001475 oxazolidinediones Chemical class 0.000 title 1
- 150000001467 thiazolidinediones Chemical class 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- PQBVPYCBEZESNR-UHFFFAOYSA-N 3-benzyl-5-phenoxy-1,3-oxazolidine-2,4-dione Chemical compound O=C1N(CC=2C=CC=CC=2)C(=O)OC1OC1=CC=CC=C1 PQBVPYCBEZESNR-UHFFFAOYSA-N 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 102000000536 PPAR gamma Human genes 0.000 abstract 1
- 108010016731 PPAR gamma Proteins 0.000 abstract 1
- -1 Phenoxyphenyl Chemical group 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000004031 partial agonist Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/44—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/62—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings
- C07D263/64—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings linked in positions 2 and 2' by chains containing six-membered aromatic rings or ring systems containing such rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53763004P | 2004-01-20 | 2004-01-20 | |
| PCT/US2005/001344 WO2005070905A1 (en) | 2004-01-20 | 2005-01-18 | Antidiabetic oxazolidinediones and thiazolidinediones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20063720L true NO20063720L (no) | 2006-10-09 |
Family
ID=34807112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20063720A NO20063720L (no) | 2004-01-20 | 2006-08-18 | Antidiabetiske oksazolidiendioner og tiazolidiendioner |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20070173434A1 (zh) |
| EP (1) | EP1709014B1 (zh) |
| JP (1) | JP2007518803A (zh) |
| KR (1) | KR20060128921A (zh) |
| CN (1) | CN100451008C (zh) |
| AT (1) | ATE363475T1 (zh) |
| AU (1) | AU2005206540B2 (zh) |
| BR (1) | BRPI0506919A (zh) |
| CA (1) | CA2553405A1 (zh) |
| CY (1) | CY1106757T1 (zh) |
| DE (1) | DE602005001265T2 (zh) |
| DK (1) | DK1709014T3 (zh) |
| ES (1) | ES2287908T3 (zh) |
| IL (1) | IL176878A0 (zh) |
| MX (1) | MXPA06008190A (zh) |
| NO (1) | NO20063720L (zh) |
| NZ (1) | NZ548556A (zh) |
| PL (1) | PL1709014T3 (zh) |
| PT (1) | PT1709014E (zh) |
| RU (1) | RU2355682C2 (zh) |
| WO (1) | WO2005070905A1 (zh) |
| ZA (1) | ZA200605512B (zh) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006138328A1 (en) * | 2005-06-14 | 2006-12-28 | Merck & Co., Inc. | Process for the production of antidiabetic oxazolidinediones |
| AU2006269503A1 (en) | 2005-07-06 | 2007-01-18 | Merck & Co., Inc. | Antidiabetic oxazolidinediones and thiazolidinediones |
| CA2612984A1 (en) * | 2005-07-20 | 2007-02-15 | Merck & Co., Inc. | Antidiabetic oxazolidinediones and thiazolidinediones |
| WO2008096769A1 (ja) * | 2007-02-08 | 2008-08-14 | Daiichi Sankyo Company, Limited | 置換されたセルコスポラミド誘導体を含有する医薬 |
| US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| AU2019282727A1 (en) | 2018-06-06 | 2020-11-26 | Metavant Sciences Gmbh | Methods of treating subjects having diabetes with chronic kidney disease |
| MX2020013567A (es) | 2018-06-14 | 2021-05-27 | Poxel | Tableta recubierta con pelicula que comprende un derivado de triazina para su uso en el tratamiento de la diabetes. |
| CN111892569A (zh) * | 2019-05-05 | 2020-11-06 | 石家庄圣泰化工有限公司 | 4,4’-联-1,3-二氧戊环-2,2’-二酮的合成方法 |
| CN112898265A (zh) * | 2019-11-18 | 2021-06-04 | 石家庄圣泰化工有限公司 | 4,4’-联-1,3-二氧戊环-2,2’-二酮的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07138258A (ja) * | 1993-11-16 | 1995-05-30 | Taiho Yakuhin Kogyo Kk | チアゾリジンジオン誘導体又はその塩 |
| US6114526A (en) * | 1996-07-01 | 2000-09-05 | Dr. Reddy's Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
| WO1999032465A1 (en) * | 1997-12-19 | 1999-07-01 | Merck & Co., Inc. | Arylthiazolidinedione derivatives |
| WO2003018135A1 (en) * | 2001-08-24 | 2003-03-06 | Wyeth Holdings Corporation | Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase |
-
2005
- 2005-01-18 PL PL05722436T patent/PL1709014T3/pl unknown
- 2005-01-18 DK DK05722436T patent/DK1709014T3/da active
- 2005-01-18 BR BRPI0506919-0A patent/BRPI0506919A/pt not_active IP Right Cessation
- 2005-01-18 RU RU2006129930/04A patent/RU2355682C2/ru active
- 2005-01-18 AU AU2005206540A patent/AU2005206540B2/en not_active Ceased
- 2005-01-18 PT PT05722436T patent/PT1709014E/pt unknown
- 2005-01-18 NZ NZ548556A patent/NZ548556A/en unknown
- 2005-01-18 KR KR1020067014509A patent/KR20060128921A/ko not_active Application Discontinuation
- 2005-01-18 CA CA002553405A patent/CA2553405A1/en not_active Abandoned
- 2005-01-18 US US10/586,976 patent/US20070173434A1/en not_active Abandoned
- 2005-01-18 MX MXPA06008190A patent/MXPA06008190A/es active IP Right Grant
- 2005-01-18 JP JP2006551178A patent/JP2007518803A/ja not_active Withdrawn
- 2005-01-18 AT AT05722436T patent/ATE363475T1/de not_active IP Right Cessation
- 2005-01-18 ES ES05722436T patent/ES2287908T3/es active Active
- 2005-01-18 CN CNB2005800027164A patent/CN100451008C/zh not_active Expired - Fee Related
- 2005-01-18 EP EP05722436A patent/EP1709014B1/en active Active
- 2005-01-18 WO PCT/US2005/001344 patent/WO2005070905A1/en active IP Right Grant
- 2005-01-18 DE DE602005001265T patent/DE602005001265T2/de not_active Expired - Fee Related
-
2006
- 2006-07-04 ZA ZA200605512A patent/ZA200605512B/en unknown
- 2006-07-16 IL IL176878A patent/IL176878A0/en unknown
- 2006-08-18 NO NO20063720A patent/NO20063720L/no not_active Application Discontinuation
-
2007
- 2007-07-24 CY CY20071100991T patent/CY1106757T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0506919A (pt) | 2007-06-05 |
| IL176878A0 (en) | 2006-10-31 |
| RU2355682C2 (ru) | 2009-05-20 |
| PT1709014E (pt) | 2007-08-13 |
| DK1709014T3 (da) | 2007-09-10 |
| AU2005206540B2 (en) | 2009-01-08 |
| KR20060128921A (ko) | 2006-12-14 |
| US20070173434A1 (en) | 2007-07-26 |
| PL1709014T3 (pl) | 2007-10-31 |
| ES2287908T3 (es) | 2007-12-16 |
| NZ548556A (en) | 2009-03-31 |
| JP2007518803A (ja) | 2007-07-12 |
| WO2005070905A1 (en) | 2005-08-04 |
| MXPA06008190A (es) | 2006-08-31 |
| DE602005001265D1 (de) | 2007-07-12 |
| EP1709014A1 (en) | 2006-10-11 |
| AU2005206540A1 (en) | 2005-08-04 |
| RU2006129930A (ru) | 2008-02-27 |
| CA2553405A1 (en) | 2005-08-04 |
| ZA200605512B (en) | 2007-11-28 |
| CN100451008C (zh) | 2009-01-14 |
| CN1910163A (zh) | 2007-02-07 |
| ATE363475T1 (de) | 2007-06-15 |
| EP1709014B1 (en) | 2007-05-30 |
| DE602005001265T2 (de) | 2008-01-31 |
| CY1106757T1 (el) | 2012-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20063720L (no) | Antidiabetiske oksazolidiendioner og tiazolidiendioner | |
| NO20075000L (no) | Kondenserte aromatiske forbindelser med anti-diabetisk aktivitet | |
| WO2006014262A3 (en) | Indoles having anti-diabetic activity | |
| WO2004019869A3 (en) | Indoles having anti-diabetic activity | |
| NO20051546L (no) | Indoler med anti-diabetisk aktivitet | |
| WO2004066963A3 (en) | N-cyclohexylaminocarbonyl benzenesulfonamide derivatives | |
| PE20060415A1 (es) | Compuestos heteroaril- y fenilsulfamoilo sustituidos | |
| MA27317A1 (fr) | Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase 1 utiles pour le traitement du diabete, de l'obesite et de la dyslipidemie | |
| ATE472531T1 (de) | Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1 | |
| ATE345128T1 (de) | Modulatoren der peroxisom-proliferator- aktivierten rezeptoren (ppar) | |
| NO20010628L (no) | Substituerte oksazol- og thiazolderivater som hPPAR <gamma> og hPPAR <alfa> aktivatorer | |
| NO20054396D0 (no) | 3-metyl-2-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksankarbonyl-amino)-smorsyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose | |
| NO20081821L (no) | Forbindelser for behandling av metabolske forstyrrelser | |
| BR0213253A (pt) | Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento de condições mediadas por receptores nucleares e de diabetes tipo i, diabetes tipo ii, dislipidemia, sìndrome x (incluindo a sìndrome metabólica, i.e. tolerância prejudicada à glicose, resistência á insulina, hipertrigliceridemia e/ou ou obesidade), doenças cardiovasculares (incluindo aterosclerose) ou hipercolesteremia | |
| DK1789403T3 (da) | N-(phenyl-oxazol-4ylmethoxymethyl)-cyclohexyl-ravsyreamid derivater og beslægtede forbindelser som PPAR-ligander (peroxisom-proliferator-aktiverede receptorer) til behandling af hyperlipidæmi og diabetes | |
| ATE327983T1 (de) | Thia- und oxazole und deren verwendung als ppars- aktivatoren | |
| ATE382043T1 (de) | Sulfonamid-derivate als ppar-modulatoren | |
| BR0211414A (pt) | Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e de diabetes tipo i, diabetes tipo ii, tolerância à glicose, resistência à insulina ou obesidade prejudicadas | |
| WO2007018956A3 (en) | Antidiabetic oxazolidinediones and thiazolidinediones | |
| ATE515494T1 (de) | Neue verbindungen, deren herstellung und verwendung | |
| WO2006022954A3 (en) | Benzoureas having anti-diabetic activity | |
| WO2004037776A3 (en) | Novel compounds and their use as prar-modulators | |
| DE602005024539D1 (de) | Neue verbindungen, ihre herstellung und verwendung | |
| DE602005022585D1 (de) | Phenoxyessigsäurederivate als ppar-agonisten | |
| NO20074738L (no) | Aktivator for peroksisom-proliferator som aktiverer reseptor delta |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |